Tinjauan atas Ezelin® – Biosimilar Insulin Glargine Pertama di Indonesia

Authors

  • Martinova Sari Panggabean Medical Department PT. Kalbe Farma, Tbk., Jakarta, Indonesia

DOI:

https://doi.org/10.55175/cdk.v45i10.716

Keywords:

Diabetes melitus, insulin, insulin basal, insulin glargine, biosimilar

Abstract

Diabetes melitus (DM) merupakan suatu kelompok penyakit metabolik dengan karakteristik hiperglikemia karena kelainan sekresi insulin, kinerja insulin atau keduanya. Salah satu terapi diabetes melitus adalah insulin. Tujuan terapi insulin adalah menirukan pola sekresi insulin endogen individu normal. Insulin glargine merupakan insulin basal kerja panjang yang memiliki masa kerja hingga 24 jam dalam mengendalikan glukosa darah puasa. Saat ini telah tersedia insulin basal biosimilar dari insulin glargine.

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Insulin treatment is a component of diabetes treatment. The aim of insulin therapy is to mimic physiologic insulin profile through insulin replacement. Insuline glargine is a long-acting basal insulin which lasts up to 24 hours. Recently, biosimolar insulin glargine has been manufactured and distributed in Indonesia.

Downloads

Download data is not yet available.

References

PERKENI. Konsensus pengelolaan diabetes melitus tipe-2 di Indonesia; 2015.

Ahmed AM. History of diabetes mellitus; abstract. Saudi Med J. 2002 Apr;23(4):373-8. [cited August 2018]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11953758.

Hingenfeld R et al. The evolution of insulin glargine and its continuing contibution to diabetes care. 2014. [cited August 2018]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045187/

Riskesdas. Riset kesehatan dasar. 2013. Kementerian Kesehatan Republik Indonesia.

International Diabetes Federation (IDF). IDF Diabetes Atlas, 7th ed. 2015. [cited August 2018]. Available from: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2018; 41(Suppl. 1).

DeFronzo RA.. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58: 773-795.

PERKENI. Konsensus pengelolaan diabetes melitus tipe-2 di Indonesia; 2011

PERKENI. Petunjuk praktis penggunaan insulin; 2015

Product Knowledge Ezelin®. Jakarta, Indonesia: PT.Kalbe Farma Tbk 2017

Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. 2004. [cited August 2018]. Available from: https://www.medscape.com/viewarticle/466194_4

Bahendeka S et al. EADSG guidelines: insulin therapy in diabetes. Diabetes Ther 2018;9:449–492. [cited August 2018]. Available from: https://link.springer.com/article/10.1007/s13300-018-0384-6.

Downloads

Published

01-10-2018

How to Cite

Panggabean, M. S. (2018). Tinjauan atas Ezelin® – Biosimilar Insulin Glargine Pertama di Indonesia. Cermin Dunia Kedokteran, 45(10), 784–788. https://doi.org/10.55175/cdk.v45i10.716